logo

For the Inventor, By the Inventor

Larchmont, NY, United States of America

Samuel D Wright

This inventor holds 13 USPTO granted patents. Top assignees: The Rockefeller University, Amgen Inc., Scripps Research Institute. Active years: 1992-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Samuel D Wright. Retrieved from https://idiyas.com/inventor/samuel-d-wright

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 13

% Patents Active = 92.3

Average Co-Inventor Count = 2.7

ph-index = 6

Forward Citations = 100(Granted Patents)


Location History:

  • Larchmont, NY (US) (1995 - 1999)
  • Westfield, NJ (US) (1999)
  • New York, NY (US) (1992 - 2002)

Company Filing History:

goldMedal7 out of 751 
 
The Rockefeller University
 patents
silverMedal4 out of 2,069 
 
Amgen Inc.
 patents
bronzeMedal3 out of 1,206 
 
Scripps Research Institute
 patents
4. 1 out of 834,453 
Other
 patents
where one patent can have more than one assignee

Years Active: 1992-2002

Loading Chart...
13 patents (USPTO):Explore Patents
1. 6495332 - Methods and compositions for ameliorating the symptoms of sepsis (2002-12-17),
2. 6297049 - Methods and compositions for ameliorating the symptoms of sepsis (2001-10-02),
3. 6045795 - Methods and compositions for ameliorating the symptoms of sepsis (2000-04-04),
4. 5932536 - Compositions for neutralization of lipopolysaccharides (1999-08-03),
5. 5928624 - Compositions for neutralization of lipopolysaccharides (1999-07-27),
6. 5869055 - Anti-inflammatory CD14 polypeptides (1999-02-09),
7. 5767243 - Afamin: a human serum albumin-like protein (1998-06-16),
8. 5766593 - Anti-inflammatory CD14 peptides (1998-06-16),
9. 5730980 - Methods and compositions for ameliorating the symptoms of sepsis (1998-03-24),
10. 5652352 - Afamin: a human serum albumin-like gene (1997-07-29),
11. 5436321 - Antibodies to the lipopolysaccharide bonding opsonin septin (1995-07-25),
12. 5322699 - Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1) (1994-06-21),
13. 5147637 - Method of inhibiting the influx of leukocytes into organs during sepsis (1992-09-15),

Title: The Innovations of Samuel D Wright

Introduction

Samuel D Wright is a notable inventor based in Larchmont, NY (US). He has made significant contributions to the field of medical science, particularly in the treatment of sepsis. With a total of 13 patents to his name, Wright's work has the potential to impact patient care and treatment methodologies.

Latest Patents

One of his latest patents focuses on methods and compositions for ameliorating the symptoms of sepsis. This invention involves a method of treating sepsis by administering a therapeutically effective amount of anti-CD14 antibody molecules. Additionally, it contemplates a therapeutic composition comprising these antibody molecules in a pharmaceutically acceptable excipient. This innovative approach aims to provide new avenues for treating a condition that affects many patients worldwide.

Career Highlights

Throughout his career, Samuel D Wright has worked with prestigious institutions, including The Rockefeller University and Amgen Inc. His experience in these organizations has allowed him to develop and refine his inventions, contributing to advancements in medical treatments.

Collaborations

Wright has collaborated with esteemed colleagues such as Richard J Ulevitch and Peter S Tobias. These partnerships have likely enriched his research and innovation processes, leading to the development of impactful medical solutions.

Conclusion

Samuel D Wright's contributions to the field of medical science through his patents and collaborations highlight his dedication to improving patient outcomes. His innovative methods for treating sepsis represent a significant advancement in medical technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…